Who are we? ChiraTecnics was founded in 2009 as a spin-out from the University of Évora, with the aim to manufacture and commercialise ligands, building blocks and catalysts (particularly OrganoCatalysts) for chiral synthesis. We also focus on custom synthesis programmes to support medicinal chemistry and drug discovery projects for pharmaceutical and biotech companies. It is led by a strong international team and has access to all vital equipment to implement our projects. We are currently very interested in the development of efficient organocatalytic systems. The company is already well established in the market. We offer cutting edge chemical technologies, with extensive know-how and experience, to rapidly respond to our customer’s needs applying the highest standards at the most affordable price. We also have access to an affordable highly qualified work-force and have a variety of proprietary technologies at our disposal. We work under complete confidentiality and pride ourselves as a trustworthy business, which takes on almost any kind of chemistry project. |
News October 2022 Our publicaton was accepted for the cover of the 17th edition: Thieme E-Journals - Synlett / Abstract (thieme-connect.com), August 2022 Check out our recent publication. Thieme E-Journals - Synlett / Abstract (thieme-connect.com) July 2022 This excellent perspective article by David Hughes shows the importance of organocatalysis in industry: April 2022 We presented communications on our latest results with immobilized cinchona-squaramide ligands at the 14 National Meeting of the Portuguese Chemical Society. Oct 2021 The Nobel Prize went to List and MacMillan for their discovery of "Asymmetric OrganoCatalyzed Reactions", an activity that Chiratecnics is involved in. For more info see: September 2021 We are really pleased with our recent publication in J. Org. Chem. Recent Advances in Asymmetric Hydrogenation Catalysis Utilizing Spiro and Other Rigid C-Stereogenic Phosphine Ligands | The Journal of Organic Chemistry (acs.org) April 2021 We have updated out catalogue with 4 new organocatalysts for aminoorganocatalysis: they are CTOrgCat6, CTOrgCat7, CTOrgCat8 and CTOrgCat9. December 2020 We are currently running a production campaign for Bis(diphenylphosphine)pyrrolidine, PyrPhos (CTCL1 and CTCL1') please contact us for a quote. We can provide in multigram quantities. November 2020 Our molecule of the month is DioxPhos (CTCL2); a great substitute for DIOP. Have you screened it in your hydrogenations? We can provide in multigram quantities. https://pt.linkedin.com/company/chiratecnics September 2020 We can provide multi-gram quantities of our aminoacid building block CTSBB1 (See our small building blocks list and also check Tetrahedron 69, 10091-10097 (2013)). June 2020 We are one of the sponsors of the forthcoming ISySyCat21 conference. See: http://isysycat2021.events.chemistry.pt/
|
|
 |
|
|
Did you Know?
TThat about 80% of APIs on the market exist as a single enantiomer (just as one mirror image isomer or one hand). In 2004, 9 of the 10 most sold drugs on the market were chiral, and most of these existed as the single enantiomer. 90% of the chemicals on the market in 2011 were derived from catalytic methods. The 3 current pillars of Catalysis are: metal based catalysis, biocatalysis and organocatalysis. The CRO Market for API and other chemicals is pretty stable at the current time. Revenues in 2010 were $11.43 billion and it is estimated to reach $20.09 billion in 2020. Pharma is outsourcing more and more business to competent CROs. |
Our mission is to provide
|
|